Glucose variability for cardiovascular risk factors in type 2 diabetes: a meta-analysis.

Shuang Liang, Hang Yin, Chunxiang Wei, Linjun Xie, Hua He, Xiaoquan Liu
Author Information
  1. Shuang Liang: Department of Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
  2. Hang Yin: Department of Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
  3. Chunxiang Wei: Department of Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
  4. Linjun Xie: Department of Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
  5. Hua He: Department of Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
  6. Xiaoquan Liu: Department of Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China. ORCID

Abstract

AIMS: It is consensus that glucose variability (GV) plays an important role in maccomplications of type 2 diabetes, but whether GV has a causal role is not yet clear for cardiovascular disease (CVD). This study sought to explore the effect on GV for CVD risk factors with type 2 diabetes.
METHODS: The systematic literature search was performed to identify all GV and CVD risk factors, including total cholesterol (TC), LDL cholesterol (LDL-C), triglyceride (TG), HDL cholesterol (HDL-C), Body Mass Index (BMI), waist circumference (WC), High-Sensitivity C-reactive protein (Hs-CRP), Homeostasis model assessment (HOMA) and carotid intima-media thickness (IMT). Preferred Reporting Items was synthesized for Systematic reviews and Meta Analyses guideline. And the pooled analyses were undertaken using Review Manager 5.3.
RESULTS: Twenty two studies were included with a total of 1143 patients in high glucose variability group (HGVG) and 1275 patients low glucose variability group (LGVG). Among these selected CVD risk factors, HOMA-IR and reduced IMT were affected by GV. HOMA-IR level was significantly lower in LGVG than in HGVG (MD = 0.58, 95% CI: 0.26 to 0.91,  = 0.0004), with evidence of heterogeneity between studies (I = 0%;  = 0.47).Reduced IMT level was significantly lower in LGVG than in HGVG (SMD = 0.28, 95% CI: 0.09 to 0.47,  = 0.003), with evidence of heterogeneity between studies (I = 0%;  = 0.48). However, the others were no significant statistical difference.
CONCLUSIONS: Among these selected CVD risk factors in type 2 diabetes, minimizing GV could improve insulin resistance and reduced IMT, consistent with a lowering in risk of CVD.

References

  1. Diabetes Care. 2014 Nov;37(11):2909-18 [PMID: 25071075]
  2. Nat Rev Mol Cell Biol. 2008 May;9(5):367-77 [PMID: 18401346]
  3. J Diabetes Complications. 2011 Sep-Oct;25(5):332-8 [PMID: 21813293]
  4. Ann Clin Biochem. 2016 Mar;53(Pt 2):240-51 [PMID: 25732129]
  5. PLoS One. 2015 Jun 08;10(6):e0129265 [PMID: 26053836]
  6. Diabet Med. 2006 Jun;23 (6):609-16 [PMID: 16759301]
  7. Am J Public Health. 1991 Sep;81(9):1158-62 [PMID: 1951827]
  8. Diabetes Res Clin Pract. 2011 Jan;91(1):e4-7 [PMID: 20970870]
  9. Diabetes Technol Ther. 2017 Aug;19(8):443-445 [PMID: 28817341]
  10. Clin Exp Pharmacol Physiol. 2010 May;37(5-6):564-8 [PMID: 20082624]
  11. Curr Vasc Pharmacol. 2012 Nov;10(6):684-6 [PMID: 23259553]
  12. Diabetes Technol Ther. 2013 Oct;15(10):810-6 [PMID: 24050737]
  13. Am J Clin Nutr. 2015 Oct;102(4):780-90 [PMID: 26224300]
  14. Diabetes Care. 2006 Dec;29(12):2625-31 [PMID: 17130195]
  15. Diabetes Care. 2009 Dec;32(12):2168-73 [PMID: 19741188]
  16. Cardiovasc Diabetol. 2016 Jan 16;15:7 [PMID: 26772807]
  17. Endocrinol Metab (Seoul). 2015 Jun;30(2):167-74 [PMID: 26194076]
  18. Arterioscler Thromb Vasc Biol. 2012 May;32(5):1124-31 [PMID: 22426129]
  19. Int J Mol Sci. 2014 Oct 13;15(10):18381-406 [PMID: 25314300]
  20. N Engl J Med. 2009 Jan 8;360(2):129-39 [PMID: 19092145]
  21. N Engl J Med. 2008 Jun 12;358(24):2545-59 [PMID: 18539917]
  22. Curr Med Res Opin. 2016 Aug;32(8):1389-96 [PMID: 27052634]
  23. BMJ. 2003 Sep 6;327(7414):557-60 [PMID: 12958120]
  24. Curr Hypertens Rep. 2003 Oct;5(5):386-92 [PMID: 12948431]
  25. Nutrition. 2016 Oct;32(10 ):1138-43 [PMID: 27155954]
  26. Diabetes Obes Metab. 2010 Apr;12(4):288-98 [PMID: 20380649]
  27. Curr Cardiol Rep. 2016 Nov;18(11):105 [PMID: 27612474]
  28. N Engl J Med. 2008 Jun 12;358(24):2560-72 [PMID: 18539916]
  29. Circulation. 2007 Jan 2;115(1):114-26 [PMID: 17192512]
  30. BMJ. 2000 Aug 12;321(7258):405-12 [PMID: 10938048]
  31. Circulation. 2007 Jan 30;115(4):459-67 [PMID: 17242284]
  32. Diabetes Care. 2011 Apr;34(4):855-7 [PMID: 21447661]
  33. Diabetes Care. 2016 Jan;39(1):92-100 [PMID: 26577417]
  34. Diabetes Care. 2002 Jul;25(7):1135-41 [PMID: 12087010]
  35. J Diabetes Res. 2016;2016:9849328 [PMID: 26798658]
  36. J Clin Epidemiol. 2009 Oct;62(10):e1-34 [PMID: 19631507]
  37. Cardiovasc Diabetol. 2011 Feb 25;10 :19 [PMID: 21349201]
  38. Diabetes Care. 2016 Jan;39(1):139-48 [PMID: 26628419]
  39. Diabetes Res Clin Pract. 2008 Oct;82(1):73-9 [PMID: 18701183]
  40. BMJ. 1997 Sep 13;315(7109):629-34 [PMID: 9310563]
  41. Endocr J. 2015;62(9):817-34 [PMID: 26194272]
  42. Circulation. 2005 Jul 5;112(1):25-31 [PMID: 15983251]
  43. Circulation. 2010 Aug 24;122(8):844-6 [PMID: 20733112]

Word Cloud

Created with Highcharts 10.0.0GVCVDriskfactorsvariabilitytype2IMT0 = 0glucosediabetescholesterolstudiesHGVGLGVGrolecardiovasculartotalpatientsgroupAmongselectedHOMA-IRreducedlevelsignificantlylower95%CI:evidenceheterogeneityI = 0%47AIMS:consensusplaysimportantmaccomplicationswhethercausalyetcleardiseasestudysoughtexploreeffectMETHODS:systematicliteraturesearchperformedidentifyincludingTCLDLLDL-CtriglycerideTGHDLHDL-CBodyMassIndexBMIwaistcircumferenceWCHigh-SensitivityC-reactiveproteinHs-CRPHomeostasismodelassessmentHOMAcarotidintima-mediathicknessPreferredReportingItemssynthesizedSystematicreviewsMetaAnalysesguidelinepooledanalysesundertakenusingReviewManager53RESULTS:Twentytwoincluded1143high1275lowaffectedMD = 05826910004ReducedSMD = 0280900348HoweverotherssignificantstatisticaldifferenceCONCLUSIONS:minimizingimproveinsulinresistanceconsistentloweringGlucosediabetes:meta-analysis

Similar Articles

Cited By (26)